FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3209917967> ?p ?o ?g. }

• W3209917967 abstract "Although various third-line treatments of advanced gastric cancer (AGC) significantly improved the overall survival, the optimal regimen has not been determined by now. This study aims to evaluate the efficacy and safety of multiple third-line treatments of AGC via integrated analysis and network meta-analysis (NMA) to provide valuable evidence for the optimal third-line systemic therapy for AGC.By searching the databases of PubMed, Embase and the Cochrane Central Register of Controlled Trials from Jan 01, 2005 to Dec 31, 2020, we included phase II/III randomized clinical trials (RCTs) of the third-line treatments for AGC to perform NMA. The main outcomes for NMA were median overall survival (mOS), median progression-free survival (mPFS), disease control rate (DCR) and adverse events (AEs). We also included phase IB/II non-RCTs and II/III RCTs of the third-line immune checkpoint inhibitors (ICIs) for integrated analysis for pooled mOS (POS), pooled mPFS (PPFS) and other outcomes.Eight phase II/III RCTs and 2 ICIs-related phase IB/II non-RCTs were included for analysis, involving 9 treatment regimens and 3012 AGC patients. In terms of mOS, apatinib (hazard ratio [HR] 0.61, 95% credible interval [CrI] 0.48-0.78) and nivolumab (HR 0.62, 95% CrI 0.51-0.76) were the most effective treatments compared with placebo. Apatinib also significantly improved mPFS versus placebo (HR 0.38, 95% CrI 0.29-0.49). Nivolumab ranked first among all regimens for 1-year OS rate and achieved the best OS in patients with HER-2 positive tumor, patients with gastroesophageal junction (GEJ) cancer and patients without gastrectomy history. TAS-102 (OR 7.46, 95% CrI 4.61-12.51) was the most toxic treatment in terms of AEs of grade 3 and higher (≥3 AEs). Pembrolizumab was more likely to cause immune related adverse event. Finally, the POS, pooled 1-year OS rate, pooled ORR and PPFS of AGC patients treated with third-line ICIs were 5.1 months, 25%, 10% and 1.71 months respectively.Apatinib and nivolumab are the most effective treatments for the third-line treatment of AGC in contrast to the third-line chemotherapy. For AGC patients with HER-2 positive tumor, patients with GEJ cancer and patients without gastrectomy history, ICIs could be the optimal third-line treatment choice." @default.
• W3209917967 created "2021-11-08" @default.
• W3209917967 creator A5026143070 @default.
• W3209917967 creator A5040773949 @default.
• W3209917967 creator A5060901085 @default.
• W3209917967 creator A5070432677 @default.
• W3209917967 creator A5077369858 @default.
• W3209917967 creator A5077656432 @default.
• W3209917967 creator A5079974007 @default.
• W3209917967 creator A5084395078 @default.
• W3209917967 creator A5086703398 @default.
• W3209917967 creator A5088911520 @default.
• W3209917967 date "2021-10-22" @default.
• W3209917967 modified "2023-09-24" @default.
• W3209917967 title "Comparison of Efficacy and Safety of Third-Line Treatments for Advanced Gastric Cancer: A Systematic Review With Bayesian Network Meta-Analysis" @default.
• W3209917967 cites W1617328014 @default.
• W3209917967 cites W1920099977 @default.
• W3209917967 cites W2010699829 @default.
• W3209917967 cites W2019607817 @default.
• W3209917967 cites W2036755924 @default.
• W3209917967 cites W2057008528 @default.
• W3209917967 cites W2075535893 @default.
• W3209917967 cites W2093223772 @default.
• W3209917967 cites W2094968190 @default.
• W3209917967 cites W2105669432 @default.
• W3209917967 cites W2113935263 @default.
• W3209917967 cites W2114101532 @default.
• W3209917967 cites W2114734455 @default.
• W3209917967 cites W2125435699 @default.
• W3209917967 cites W2134392974 @default.
• W3209917967 cites W2144625636 @default.
• W3209917967 cites W2145390243 @default.
• W3209917967 cites W2146471523 @default.
• W3209917967 cites W2172255378 @default.
• W3209917967 cites W2276228008 @default.
• W3209917967 cites W2347070489 @default.
• W3209917967 cites W2472847770 @default.
• W3209917967 cites W2479956840 @default.
• W3209917967 cites W2515452405 @default.
• W3209917967 cites W2558697804 @default.
• W3209917967 cites W2618726964 @default.
• W3209917967 cites W2735126203 @default.
• W3209917967 cites W2763064222 @default.
• W3209917967 cites W2793364080 @default.
• W3209917967 cites W2808750176 @default.
• W3209917967 cites W2883552436 @default.
• W3209917967 cites W2891942735 @default.
• W3209917967 cites W2897154408 @default.
• W3209917967 cites W2912776918 @default.
• W3209917967 cites W2953426736 @default.
• W3209917967 cites W2962838796 @default.
• W3209917967 cites W2968227241 @default.
• W3209917967 cites W2978212924 @default.
• W3209917967 cites W2981623163 @default.
• W3209917967 cites W2992615845 @default.
• W3209917967 cites W2994683483 @default.
• W3209917967 cites W3020689019 @default.
• W3209917967 cites W3024911178 @default.
• W3209917967 cites W3036571927 @default.
• W3209917967 cites W3093358459 @default.
• W3209917967 cites W3107413524 @default.
• W3209917967 cites W3112153165 @default.
• W3209917967 cites W3128646645 @default.
• W3209917967 cites W4205314496 @default.
• W3209917967 doi "https://doi.org/10.3389/fonc.2021.734323" @default.
• W3209917967 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8570109" @default.
• W3209917967 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34745955" @default.
• W3209917967 hasPublicationYear "2021" @default.
• W3209917967 type Work @default.
• W3209917967 sameAs 3209917967 @default.
• W3209917967 citedByCount "5" @default.
• W3209917967 countsByYear W32099179672022 @default.
• W3209917967 countsByYear W32099179672023 @default.
• W3209917967 crossrefType "journal-article" @default.
• W3209917967 hasAuthorship W3209917967A5026143070 @default.
• W3209917967 hasAuthorship W3209917967A5040773949 @default.
• W3209917967 hasAuthorship W3209917967A5060901085 @default.
• W3209917967 hasAuthorship W3209917967A5070432677 @default.
• W3209917967 hasAuthorship W3209917967A5077369858 @default.
• W3209917967 hasAuthorship W3209917967A5077656432 @default.
• W3209917967 hasAuthorship W3209917967A5079974007 @default.
• W3209917967 hasAuthorship W3209917967A5084395078 @default.
• W3209917967 hasAuthorship W3209917967A5086703398 @default.
• W3209917967 hasAuthorship W3209917967A5088911520 @default.
• W3209917967 hasBestOaLocation W32099179671 @default.
• W3209917967 hasConcept C121608353 @default.
• W3209917967 hasConcept C126322002 @default.
• W3209917967 hasConcept C142724271 @default.
• W3209917967 hasConcept C143998085 @default.
• W3209917967 hasConcept C168563851 @default.
• W3209917967 hasConcept C197934379 @default.
• W3209917967 hasConcept C204787440 @default.
• W3209917967 hasConcept C207103383 @default.
• W3209917967 hasConcept C27081682 @default.
• W3209917967 hasConcept C2777701055 @default.
• W3209917967 hasConcept C2780030458 @default.
• W3209917967 hasConcept C2780668389 @default.
• W3209917967 hasConcept C2781413609 @default.
• W3209917967 hasConcept C44249647 @default.
• W3209917967 hasConcept C71924100 @default.

• next